<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318887</url>
  </required_header>
  <id_info>
    <org_study_id>CRC_GHN_2016_001</org_study_id>
    <nct_id>NCT03318887</nct_id>
  </id_info>
  <brief_title>Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA</brief_title>
  <official_title>Sofosbuvir Plus Daclatasvir With or Without Ribavirin for Chronic Hepatitis C Infection: Impact of Drug Concentration on Viral Load Decay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended
      treatment option for chronic hepatitis C. The objectives were to identify factors associated
      with sofosbuvir/daclatasvir plasma concentrations variations and to evaluate their impact on
      viral kinetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2014</start_date>
  <completion_date type="Actual">June 30, 2015</completion_date>
  <primary_completion_date type="Actual">September 30, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sofosbuvir/daclatasvir plasma concentration</measure>
    <time_frame>Sofosbuvir/daclatasvir plasma concentrations were measured at week 4, 8, 12 and 24 during therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV viral load</measure>
    <time_frame>At treatment initiation, at week 4, 8, 12 and 24 of therapy and 12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir/daclatasvir</arm_group_label>
    <description>Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/daclatasvir with or without ribavirin</intervention_name>
    <description>Direct-acting antiviral treatment for hepatitis C virus infection</description>
    <arm_group_label>Sofosbuvir/daclatasvir</arm_group_label>
    <other_name>Combination of sofosbuvir and daclatasvir with or without ribavirin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All HCV infected patients from the Department of Hepatology, Croix-Rousse Hospital, Lyon,
        France receiving sofosbuvir/daclatasvir with or without ribavirin between February and
        September 2014 were considered
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hepatitis C virus infection treated with sofosbuvir/daclatasvir

          -  Patients with at least one measurement of sofosbuvir or daclatasvir plasma
             concentration

          -  Follow-up of at least 3 months after the end of treatment

        Exclusion Criteria:

          -  Patients with severe renal failure (estimated glomerular filtration rate
             (eGFR)&lt;30ml/min/1.73m2)

          -  Patients with liver transplantation during therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Zoulim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Croix-Rousse Hospital, Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Direct acting antiviral agents</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Pharmacological monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

